Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder.

TL;DR: Current understanding of the AD immune map in both patients with early-onset and those with chronic disease is discussed, with a focus on a systemic treatment approach in patients with moderate-to-severe disease.

TL;DR: Dupilumab significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype, as well as suppressing cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation.

TL;DR: These data support the heavy burden that AD places on patients, particularly those with moderate and severe AD.

TL;DR: Therapies targeting different cytokine axes and other mechanisms involved in disease pathogenesis, which are currently being tested for patients with AD across the disease spectrum, will expand the ability to dissect the relative contribution of each of these pathways to disease perpetuation.

TL;DR: Using data from two population-based birth cohorts, Danielle Belgrave and colleagues examine the evidence for atopic march in developmental profiles for allergic disorders.

TL;DR: The aim of this study was to classify different courses of AD and to correlate these with specific risk factors for severe variants of AD.

TL;DR: The CVA6-associated enterovirus outbreak was responsible for an exanthem potentially more widespread, severe, and varied than classic HFMD that could be confused with bullous impetigo, eczema herpeticum, vasculitis, and primary immunobullous disease.